



Evidence-Based Series 8-6 Version 2

A Quality Initiative of the
Program in Evidence-Based Care (PEBC), Cancer Care Ontario (CCO)

Surgical Management of Patients with Lymph Node Metastases from Cutaneous Melanoma of the Trunk or Extremities

The Melanoma Disease Site Group

An assessment conducted in November 2023 deferred the review of Evidence-Based Series (EBS) 8-6 Version 2. This means that the document remains current until it is assessed again next year. The PEBC has a formal and standardized process to ensure the currency of each document ([PEBC Assessment & Review Protocol](#))

EBS 8-6 consists of 4 sections. You can access the summary and full report here:
<https://www.cancercareontario.ca/en/guidelines-advice/types-of-cancer/806>

Section 1: Guideline Recommendations (UPDATED [1b] and ENDORSED)
Section 2: Evidentiary Base
Section 3: EBS Development Methods and External Review Process
Section 4: Document Review Summary and Tool

August 31, 2018

For information about the PEBC and the most current version of all reports, please visit the CCO website at <http://www.cancercare.on.ca/> or contact the PEBC office at:
Phone: 905-527-4322 ext. 42822 Fax: 905-526-6775 E-mail: ccopgi@mcmaster.ca

Guideline Citation (Vancouver Style): Easson AM, Cosby R, McCready DR, Temple C, Petrella T, Wright F, et al. Surgical management of patients with lymph node metastases from cutaneous melanoma of the trunk or extremities. Easson A, Salerno J, reviewers. Toronto, ON: Cancer Care Ontario; 2012 Dec 4 [Endorsed 2018 Aug]. Program in Evidence-based Care Evidence-Based Series No.: 8-6 Version 2 ENDORSED.

Guideline Report History

GUIDELINE VERSION	SYSTEMATIC REVIEW		PUBLICATIONS	NOTES and KEY CHANGES
	Search Dates	Data		
Original December 2012	Jan 1980 - Sept 2011	Full Report	Web publication	NA
Version 2 June 2016	Jan 2011 - April 2016	New evidence added to Section 1 and new data found in Section 4	Updated web publication	2012 recommendations ENDORSED
Update of version 2 August 2018	NA	MSLT-II trial added to <u>Section 1</u> only	Updated web publication	Recommendation 1b updated with the data from the MSLT-II trial. For details see Appendix 3

A Quality Initiative of the
Program in Evidence-Based Care (PEBC), Cancer Care Ontario (CCO)

**Surgical Management of Patients with Lymph Node Metastases
from Cutaneous Melanoma of the Trunk or Extremities:
Guideline Recommendations**

*A.M. Easson, R. Cosby, D.R. McCreedy, C. Temple, T. Petrella, F. Wright,
and the Melanoma Disease Site Group*

Original Report Date: December 5, 2012

Evidence-Based Series (EBS) 8-6 was reviewed in 2018 and **UPDATED** by the Melanoma Disease Site Group. New evidence was added to Section 1 and recommendation 1b was updated based on new practice-changing evidence. All other recommendations have been **ENDORSED** and are relevant for decision making.

QUESTIONS

1. What is the optimal surgical management of patients with positive sentinel lymph nodes (SLNs) from cutaneous melanoma of the trunk or extremities with respect to:
 - a. Factors for predicting non-sentinel lymph node (NSLN) positivity
 - b. Completion lymph node dissection (CLND) at the time of SLN positivity versus observation
 - c. Extent of nodal dissection
2. What is the optimal surgical management of patients with biopsy-proven clinically palpable or biopsy-proven radiologically detected lymph nodes from cutaneous melanoma of the trunk or extremities with respect to:
 - a. Extent of nodal dissection

OUTCOMES OF INTEREST

The outcomes of interest for these guideline recommendations are local and regional recurrence, distant recurrence, overall survival (OS), and disease-free survival (DFS).

TARGET POPULATION

These recommendations apply to adult patients with truncal or extremity cutaneous melanoma with nodal metastases.

INTENDED USERS

These guidelines are intended for use by clinicians and healthcare providers involved in the management or referral of patients with nodal metastases from truncal or extremity cutaneous melanoma.

DEFINITIONS

- **Completion Lymph Node Dissection (CLND)** - The surgical removal of the remaining lymph nodes within an axillary or inguinal nodal basin after the identification of metastatic melanoma within a previously removed sentinel lymph node (SLN) from that same nodal basin. The axillary nodal basin is divided into three levels: level 1 nodes lie below, level 2 nodes lie behind, and level 3 nodes lie above the pectoralis minor muscle. The inguinal nodal basin includes the nodes from below/superficial to the inguinal ligament to the apex of the femoral triangle. The nodes above the inguinal ligament in the pelvis along the iliac vessels up to the common iliac bifurcation can also be considered a part of the inguinal nodal basin. If they are also removed, this is an **ilioinguinal dissection**.
- **Therapeutic Lymph Node Dissection (TLND)** - The surgical removal of all lymph nodes within an axillary or inguinal nodal basin in the presence of biopsy-proven clinically palpable, or biopsy-proven radiologically detected lymph nodes.
- **Radiologically Detected Lymph Node** - A node that was not clinically palpable but that was biopsied under radiologic guidance after appearing abnormal on radiologic imaging.
- **Cloquet's node** - The node medial to the femoral vein at the level of the inguinal ligament.

RECOMMENDATIONS AND KEY EVIDENCE

1. Patients with a positive sentinel lymph node

a. Prognostic factors for predicting non-sentinel lymph node involvement

No consistent set of factors reliably predicts non-sentinel lymph node positivity in those patients with a positive SLN.

Thirty-nine [1-39] studies, mainly retrospective, have looked at many factors that might predict further node positivity at CLND. However, no core set of features among the studies is consistently examined nor does a core set of features consistently predict further nodal positivity at CLND.

New 2018

b. Completion lymph node dissection at the time of SLN positivity versus observation

Patients with sentinel node metastasis should be considered for nodal observation with ultrasonography rather than CLND. Monitoring with ultrasonography of the affected nodal basin and clinical exam will be required, at minimum, every 4 to 6 months for the first 2 years and every 6 months from 3-5 years. Suspicions of a nodal recurrence in a lymph node basin include any two of the following: lymph node length:depth ratio <2, hypoechoic centre, failure to identify a nodal hilar vessel and/or focal rounded area of low level echoes with increased vascularity in that area. Suspicions of nodal recurrence via ultrasound should be confirmed with a biopsy of the basin. For certain patients, a CLND may still be the best option for local control but should be discussed by a multi-disciplinary team (MDT).

Qualifying Statements for Recommendation 1b

- In MSLT-II [58] one third of patients had metastases greater than 1 mm in diameter and 72% of patients had one sentinel node with metastases. A subgroup evaluation of patients with a greater disease burden (maximal tumour diameter >1 mm) did not indicate that a benefit

from completion lymph-node dissection was more likely in high-risk groups than in low-risk groups [58].

- Patients in whom CLND would be a better option than nodal observation with ultrasonography are:
 - patients with extensive sentinel node metastasis in which CLND would be the only option for local control
 - patients unlikely to be compliant with an intensive surveillance protocol
- While this guideline is specific to the trunk and extremities, this recommendation can be applied to melanomas of the head and neck and their respective drainage basins.

Key Evidence Added in the 2018 Update of Recommendation 1b

One randomized trial, MSLT-II [58] evaluated the utility of CLND compared to observation with frequent nodal ultrasonography and dissection only in melanoma patients with positive sentinel lymph node metastasis. The majority of patients in MSLT-II had low-volume nodal tumour burden (1 positive sentinel lymph node, longest diameter of the largest tumor deposit measured and the mean diameter of nodal metastasis 1.1mm). Three year MSS for the CLND and the observation group was the same, $86\pm 1.3\%$ and $86\pm 1.2\%$ ($p=0.42$), respectively. The 3-year DFS rate was slightly higher in the CLND group ($p=0.05$) but the investigators caution the significance of this result based on the lack of significance of the MSS, which was the primary outcome. The DFS rate may be explained by the lower rate of nodal failure in the CLND group as compared to the observation group at 3 years ($92\pm 1\%$ vs. $77\pm 1.5\%$; $p=0.001$). Adverse events occurred with more frequency among the CLND patients than the observation group with lymphedema being the most common (24.1% of patients vs. 6.3% at last follow-up, $p<0.001$). Non sentinel-node metastases, which was identified in 11.5% of the patients in the CLND group was found to be an independent prognostic factor for melanoma related death. Overall, some regional control and prognostic value can be derived from CLND; however, this is at the expense of increased adverse events. The non-significant difference in MSS and increase in adverse events of the CLND group indicates that CLND may not be optimal for patients and does not offer a survival benefit. Although the majority of patients had low volume tumor metastases, sub set analysis did not demonstrate a benefit for any groups of patient receiving CLND. As a result of the publication of the MSLT-II trial, the original recommendation has been altered to reflect this new high-quality evidence.

Key Evidence added in the 2016 Endorsement

The literature search conducted in 2016 to assess the validity of the current recommendations identified one randomized controlled trial that evaluated the benefit of CLND [46]. The DeCOG-SLT trial found no difference in distant metastasis-free survival, overall survival, or recurrence-free survival when SLN positive patients who received CLND were compared to patients who were observed. In this study, the majority (68% of patients) had sentinel node metastasis of $<1\text{mm}$). Although this study indicates no benefit for CLND, the study was small ($n=240$ CLND; $n=233$ observation) and included a short median follow-up time of 35 months. Due to the limitations of this study, the current recommendation was not altered.

Original Key Evidence from 2012

There are three small non-randomized studies that have evaluated the benefit of CLND versus observation [40-42]. Three papers compared CLND at time of positive SLN to those patients having a TLND for clinically palpable nodes. The largest of these ($n=2633$), a meta-analysis [43], does demonstrate a survival advantage for upfront CLND at the time of a positive

SLN (Risk of Death for TLND, hazard ratio [HR], 1.60; 95% confidence interval [CI], 1.28 to 2.00; $p < 0.0001$). This recommendation is based on this limited evidence and expert opinion.

Likewise, the few studies that evaluate the benefit of CLND over either observation or TLND with respect to recurrence are not randomized. No studies identified have reported significant differences in recurrence between CLND and observation [41-43] or CLND and TLND [40, 44, 45].

c. Extent of nodal dissection for sentinel node positive disease if being undertaken

A complete Level 1, 2 and 3 dissection in the axilla is recommended for patients with a positive SLN, pending the emergence of good quality randomized data.

An inguinal dissection is recommended for patients with a positive SLN in the groin, pending the emergence of good quality randomized data. The routine examination of Cloquet's node and the addition of iliac dissection are more controversial, and any decision regarding these procedures should be made on a case-by-case basis.

There is no clear advantage to ilioinguinal dissection [47-50] or the evaluation of Cloquet's node [51,52] with respect to survival or morbidity in the small dataset that is available. This recommendation is based on expert opinion.

2. Patients with biopsy-proven clinically or biopsy-proven radiologically detected positive nodes

A Level 1, 2 and 3 dissection in the axilla is recommended for patients with biopsy-proven clinically or biopsy-proven radiologically detected positive nodes, pending the emergence of good quality randomized data.

Extent of nodal dissection

No studies addressing this question were identified, resulting in no evidence to support or refute the extent of axillary dissection being found. However, these patients are more likely to have multiple positive nodes than those patients identified by a SLN biopsy. This recommendation is based on expert opinion.

Inguinal dissection is recommended for patients with biopsy-proven clinically or biopsy-proven radiologically detected positive inguinal lymph nodes, pending the emergence of good quality randomized data. Because there is a greater likelihood of positive ilioinguinal nodes in this clinical situation, Cloquet's node could be examined and ilioinguinal dissection undertaken if the node is positive.

In the small dataset currently available there is no clear advantage to ilioinguinal dissection [53] or the evaluation of Cloquet's node [54,55] with respect to survival or morbidity. Decisions regarding iliac dissection should be made on a case-by-case basis [56,57]. This recommendation is based on expert opinion.

FUTURE RESEARCH

The development of more consistency among studies of factors to predict additional disease in non-sentinel lymph nodes would be invaluable, not only in the selection of variables,

but also in the strict definition of the variables selected. Standardized synoptic reporting of the SLN would help bring consistency to these types of studies.

RELATED GUIDELINES

PEBC Evidence-Based Series Report (EBS):

- EBS 8-2: Primary Excision Margins and Sentinel Lymph Node Biopsy in Clinically Node-Negative Cutaneous Melanoma of the Trunk or Extremities (available from: <https://www.cancercareontario.ca/en/guidelines-advice/types-of-cancer/51116>)

Funding

The PEBC is a provincial initiative of Cancer Care Ontario supported by the Ontario Ministry of Health and Long-Term Care. All work produced by the PEBC is editorially independent from the Ontario Ministry of Health and Long-Term Care.

Updating

All PEBC documents are maintained and updated as described in the PEBC Document Assessment and Review Protocol at <https://www.cancercareontario.ca/en/cancer-care-ontario/programs/data-research/evidence-based-care>

Copyright

This report is copyrighted by Cancer Care Ontario; the report and the illustrations herein may not be reproduced without the express written permission of Cancer Care Ontario. Cancer Care Ontario reserves the right at any time, and at its sole discretion, to change or revoke this authorization.

Disclaimer

Care has been taken in the preparation of the information contained in this report. Nonetheless, any person seeking to apply or consult the report is expected to use independent medical judgment in the context of individual clinical circumstances or seek out the supervision of a qualified clinician. Cancer Care Ontario makes no representation or guarantees of any kind whatsoever regarding the report content or use or application and disclaims any responsibility for its application or use in any way.

For information about the PEBC and the most current version of all reports, please visit the CCO website at <http://www.cancercare.on.ca/> or contact the PEBC office at: Phone: 905-527-4322 ext. 42822 Fax: 905-526-6775 E-mail: ccopgi@mcmaster.ca

References

1. Joseph E, Brobeil A, Glass F, Glass J, Messina J, DeConti R, et al. Results of complete lymph node dissection in 83 melanoma patients with positive sentinel nodes. *Annals of Surgical Oncology*. 1998;5(2):119-25.
2. Starz H, Balda BR, Kramer KU, Buchels H, Wang H. A micromorphometry-based concept for routine classification of sentinel lymph node metastases and its clinical relevance for patients with melanoma. *Cancer*. 2001;91(11):2110-21.
3. McMasters KM, Wong SL, Edwards MJ, Chao C, Ross MI, Noyes RD, et al. Frequency of nonsentinel lymph node metastasis in melanoma. *Annals of Surgical Oncology*. 2002;9(2):137-41.
4. Reeves ME, Delgado R, Busam KJ, Brady MS, Coit DG. Prediction of nonsentinel lymph node status in melanoma. *Annals of Surgical Oncology*. 2003;10(1):27-31.
5. Salti GI, Das Gupta TK. Predicting residual lymph node basin disease in melanoma patients with sentinel lymph node metastases. *American Journal of Surgery*. 2003;186(2):98-101.
6. Cochran AJ, Wen D-R, Huang R-R, Wang H-J, Elashoff R, Morton DL. Prediction of metastatic melanoma in nonsentinel nodes and clinical outcome based on the primary melanoma and the sentinel node. *Modern Pathology*. 2004;17(7):747-55.
7. Dewar DJ, Newell B, Green MA, Topping AP, Powell BWEM, Cook MG. The microanatomic location of metastatic melanoma in sentinel lymph nodes predicts nonsentinel lymph node involvement. *Journal of Clinical Oncology*. 2004;22(16):3345-9.
8. Elias N, Tanabe KK, Sober AJ, Gadd MA, Mihm MC, Goodspeed B, et al. Is completion lymphadenectomy after a positive sentinel lymph node biopsy for cutaneous melanoma always necessary? *Archives of Surgery*. 2004;139(4):400-5.
9. Lee JH, Essner R, Torisu-Itakura H, Wanek L, Wang H, Morton DL. Factors predictive of tumor-positive nonsentinel lymph nodes after tumor-positive sentinel lymph node dissection for melanoma. *Journal of Clinical Oncology*. 2004;22(18):3677-84.
10. Scolyer RA, Li L-XL, McCarthy SW, Shaw HM, Stretch JR, Sharma R, et al. Micromorphometric features of positive sentinel lymph nodes predict involvement of nonsentinel nodes in patients with melanoma. *American Journal of Clinical Pathology*. 2004;122(4):532-9.
11. Starz H, Siedlecki K, Balda B-R. Sentinel lymphonodectomy and s-classification: a successful strategy for better prediction and improvement of outcome of melanoma. *Annals of Surgical Oncology*. 2004;11(3 Suppl):162S-85.
12. Fink AM, Weihsengruber F, Spangl B, Feichtinger H, Lilgenau N, Rappersberger K, et al. S-classification of sentinel lymph node biopsy predicts the results of complete regional lymph node dissection. *Melanoma Research*. 2005;15(4):267-71.
13. Sabel MS, Griffith K, Sondak VK, Lowe L, Schwartz JL, Cimmino VM, et al. Predictors of nonsentinel lymph node positivity in patients with a positive sentinel node for melanoma. *Journal of the American College of Surgeons*. 2005;201(1):37-47.
14. Vuylsteke RJCLM, Borgstein PJ, Van Leeuwen PAM, Gietema HA, Molenkamp BG, Muller MGS, et al. Sentinel lymph node tumor load: An independent predictor of additional lymph node involvement and survival in melanoma. *Annals of Surgical Oncology*. 2005;12(6):440-8.
15. Pearlman NW, McCarter MD, Frank M, Hurtubis C, Merkow RP, Franklin WA, et al. Size of sentinel node metastases predicts other nodal disease and survival in malignant melanoma. *American Journal of Surgery*. 2006;192(6):878-81.
16. van Akkooi ACJ, de Wilt JHW, Verhoef C, Schmitz PIM, van Geel AN, Eggermont AMM, et al. Clinical relevance of melanoma micrometastases (<0.1 mm) in sentinel nodes: are these nodes to be considered negative? *Annals of Oncology*. 2006;17(10):1578-85.

17. Govindarajan A, Ghazarian DM, McCready DR, Leong WL. Histological features of melanoma sentinel lymph node metastases associated with status of the completion lymphadenectomy and rate of subsequent relapse. *Annals of Surgical Oncology*. 2007;14(2):906-12.
18. Debarbieux S, Duru G, Dalle S, Beatrix O, Balme B, Thomas L. Sentinel lymph node biopsy in melanoma: a micromorphometric study relating to prognosis and completion lymph node dissection. *British Journal of Dermatology*. 2007;157(1):58-67.
19. Page AJ, Carlson GW, Delman KA, Murray D, Hestley A, Cohen C. Prediction of nonsentinel lymph node involvement in patients with a positive sentinel lymph node in malignant melanoma. *American Surgeon*. 2007;73(7):674-8.
20. Frankel TL, Griffith KA, Lowe L, Wong SL, Bichakjian CK, Chang AE, et al. Do micromorphometric features of metastatic deposits within sentinel nodes predict nonsentinel lymph node involvement in melanoma? *Annals of Surgical Oncology*. 2008;15(9):2403-11.
21. Glumac N, Hocevar M, Zadnik V, Snoj M. Sentinel lymph node micrometastasis may predict non-sentinel involvement in cutaneous melanoma patients. *Journal of Surgical Oncology*. 2008;98(1):46-8.
22. Guggenheim M, Dummer R, Jung FJ, Mihic-Probst D, Steinert H, Rousson V, et al. The influence of sentinel lymph node tumour burden on additional lymph node involvement and disease-free survival in cutaneous melanoma--a retrospective analysis of 392 cases. *British Journal of Cancer*. 2008;98(12):1922-8.
23. Roka F, Mastan P, Binder M, Okamoto I, Mittlboeck M, Horvat R, et al. Prediction of non-sentinel node status and outcome in sentinel node-positive melanoma patients. *European Journal of Surgical Oncology*. 2008;34(1):82-8.
24. Rossi CR, De Salvo GL, Bonandini E, Mocellin S, Foletto M, Pasquali S, et al. Factors predictive of nonsentinel lymph node involvement and clinical outcome in melanoma patients with metastatic sentinel lymph node.[Erratum appears in *Ann Surg Oncol*. 2008 May;15(5):1552]. *Annals of Surgical Oncology*. 2008;15(4):1202-10.
25. Satzger I, Volker B, Meier A, Kapp A, Gutzmer R. Criteria in sentinel lymph nodes of melanoma patients that predict involvement of nonsentinel lymph nodes. *Annals of Surgical Oncology*. 2008;15(6):1723-32.
26. van Akkooi ACJ, Nowecki ZI, Voit C, Schafer-Hesterberg G, Michej W, de Wilt JHW, et al. Sentinel node tumor burden according to the Rotterdam criteria is the most important prognostic factor for survival in melanoma patients: a multicenter study in 388 patients with positive sentinel nodes. *Annals of Surgery*. 2008;248(6):949-55.
27. Cadili A, Smylie M, Danyluk J, Dabbs K. Prediction of nonsentinel lymph node metastasis in malignant melanoma. *Journal of Surgical Research*. 2009;154(2):324-9.
28. Gershenwald JE, Andtbacka RHI, Prieto VG, Johnson MM, Diwan AH, Lee JE, et al. Microscopic tumor burden in sentinel lymph nodes predicts synchronous nonsentinel lymph node involvement in patients with melanoma. *Journal of Clinical Oncology*. 2008;26(26):4296-303.
29. Ollila DW, Ashburn JH, Amos KD, Yeh JJ, Frank JS, Deal AM, et al. Metastatic melanoma cells in the sentinel node cannot be ignored. *Journal of the American College of Surgeons*. 2009;208(5):924-30.
30. Santinami M, Carbone A, Crippa F, Maurichi A, Pellitteri C, Ruggeri R, et al. Radical dissection after positive groin sentinel biopsy in melanoma patients: rate of further positive nodes. *Melanoma Research*. 2009;19(2):112-8.
31. Cadili A, Dabbs K, Scolyer RA, Brown PT, Thompson JF. Re-evaluation of a scoring system to predict nonsentinel-node metastasis and prognosis in melanoma patients. *Journal of the American College of Surgeons*. 2010;211(4):522-5.

32. Cadili A, McKinnon G, Wright F, Hanna W, Macintosh E, Abhari Z, et al. Validation of a scoring system to predict non-sentinel lymph node metastasis in melanoma. *Journal of Surgical Oncology*. 2010;101(3):191-4.
33. Murali R, Desilva C, Thompson JF, Scolyer RA. Non-Sentinel Node Risk Score (N-SNORE): a scoring system for accurately stratifying risk of non-sentinel node positivity in patients with cutaneous melanoma with positive sentinel lymph nodes. *Journal of Clinical Oncology*. 2010;28(29):4441-9.
34. Wiener M, Acland KM, Shaw HM, Soong S-J, Lin H-Y, Chen D-T, et al. Sentinel node positive melanoma patients: prediction and prognostic significance of nonsentinel node metastases and development of a survival tree model. *Annals of Surgical Oncology*. 2010;17(8):1995-2005.
35. Younan R, Bougrine A, Watters K, Mahboubi A, Bouchereau-Eyegue M, Loutfi A, et al. Validation study of the s classification for melanoma patients with positive sentinel nodes: the Montreal experience. *Annals of Surgical Oncology*. 2010;17(5):1414-21.
36. Bogenrieder T, van Dijk MR, Blokk WAM, Ramrath K, Seldenrijk K, Stolz W, et al. No non-sentinel node involvement in melanoma patients with limited Breslow thickness and low sentinel node tumour load. *Histopathology*. 2011;59(2):318-26.
37. Fink AM, Wehsengruber F, Duschek N, Schierl M, Wondratsch H, Jurecka W, et al. Value of micromorphometric criteria of sentinel lymph node metastases in predicting further nonsentinel lymph node metastases in patients with melanoma. *Melanoma Research*. 2011;21(2):139-43.
38. Kunte C, Geimer T, Baumert J, Konz B, Volkenandt M, Flaig M, et al. Analysis of predictive factors for the outcome of complete lymph node dissection in melanoma patients with metastatic sentinel lymph nodes. *Journal of the American Academy of Dermatology*. 2011;64(4):655-62; quiz 37.
39. van der Ploeg APT, van Akkooi ACJ, Rutkowski P, Nowecki ZI, Michej W, Mitra A, et al. Prognosis in patients with sentinel node-positive melanoma is accurately defined by the combined Rotterdam tumor load and Dewar topography criteria. *Journal of Clinical Oncology*. 2011;29(16):2206-14.
40. Wong SL, Morton DL, Thompson JF, Gershenwald JE, Leong SPL, Reintgen DS, et al. Melanoma patients with positive sentinel nodes who did not undergo completion lymphadenectomy: a multi-institutional study. *Annals of Surgical Oncology*. 2006;13(6):809-16.
41. Kingham TP, Panageas KS, Ariyan CE, Busam KJ, Brady MS, Coit DG. Outcome of patients with a positive sentinel lymph node who do not undergo completion lymphadenectomy. *Annals of Surgical Oncology*. 2010;17(2):514-20.
42. van der Ploeg IMC, Kroon BBR, Antonini N, Valdes Olmos RA, Nieweg OE. Is completion lymph node dissection needed in case of minimal melanoma metastasis in the sentinel node? *Annals of Surgery*. 2009;249(6):1003-7.
43. Pasquali S, Mocellin S, Campana LG, Bonandini E, Montesco MC, Tregnaghi A, et al. Early (sentinel lymph node biopsy-guided) versus delayed lymphadenectomy in melanoma patients with lymph node metastases: Personal experience and literature meta-analysis. *Cancer*. 2010;116(5):1201-9.
44. Rutkowski P, Nowecki ZI, Zurawski Z, Dziewirski W, Nasierowska-Guttmejer A, Switaj T, et al. In transit/local recurrences in melanoma patients after sentinel node biopsy and therapeutic lymph node dissection. *European Journal of Cancer*. 2006;42(2):159-64.
45. Veenstra HJ, van der Ploeg IMC, Wouters MWJM, Kroon BBR, Nieweg OE. Reevaluation of the locoregional recurrence rate in melanoma patients with a positive sentinel node compared to patients with palpable nodal involvement. *Annals of Surgical Oncology*. 2010;17(2):521-6.

46. Leiter U, Stadler R, Mauch C, Hohenberger W, Brockmeyer N, Berking C, et al. Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. *Lancet Oncol.* 2016.
47. Hughes TM, Thomas JM. Combined inguinal and pelvic lymph node dissection for stage III melanoma. *British Journal of Surgery.* 1999;86(12):1493-8.
48. Zoltie N, Chapman P, Joss G. Is iliac node clearance necessary for Stage II melanoma? *Plastic & Reconstructive Surgery.* 1991;88(5):810-3.
49. Karakousis CP, Driscoll DL, Rose B, Walsh DL. Groin dissection in malignant melanoma. *Annals of Surgical Oncology.* 1994;1(4):271-7.
50. van der Ploeg IMC, Valdes Olmos RA, Kroon BBR, Nieweg OE. Tumor-positive sentinel node biopsy of the groin in clinically node-negative melanoma patients: superficial or superficial and deep lymph node dissection? *Annals of Surgical Oncology.* 2008;15(5):1485-91.
51. Essner R, Scheri R, Kavanagh M, Torisu-Itakura H, Wanek LA, Morton DL. Surgical management of the groin lymph nodes in melanoma in the era of sentinel lymph node dissection. *Archives of Surgery.* 2006;141(9):877-84.
52. Chu CK, Zager JS, Marzban SS, Gimbel MI, Murray DR, Hestley AC, et al. Routine biopsy of Cloquet's node is of limited value in sentinel node positive melanoma patients. *Journal of Surgical Oncology.* 2010;102(4):315-20.
53. Kretschmer L, Neumann C, Preusser KP, Marsch WC. Superficial inguinal and radical ilioinguinal lymph node dissection in patients with palpable melanoma metastases to the groin--an analysis of survival and local recurrence. *Acta Oncologica.* 2001;40(1):72-8.
54. Shen P, Conforti AM, Essner R, Cochran AJ, Turner RR, Morton DL. Is the node of Cloquet the sentinel node for the iliac/obturator node group? *Cancer Journal.* 2000;6(2):93-7.
55. Strobbe LJ, Jonk A, Hart AA, Peterse JL, Wobbes T, Nieweg OE, et al. The value of Cloquet's node in predicting melanoma nodal metastases in the pelvic lymph node basin. *Annals of Surgical Oncology.* 2001;8(3):209-14.
56. Holmes EC, Moseley HS, Morton DL, Clark W, Robinson D, Urist MM. A rational approach to the surgical management of melanoma. *Ann Surg.* 1977;186(4):481-90.
57. Jacobs LK, Balch CM, Coit DG. Inguinofemoral iliac/obturator, and popliteal lymphadenectomy in patients with melanoma. In: Balch CM, Houghton AN, Sober AJ, Soong SJ, editors. *St. Louis, MO: Quality Medical Publishing Inc.; 2009. p. 457-70.*
58. Faries M, Thompson J, Cochran A, Andtbacka R et al. Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. *New England Journal of Medicine.* 2017; 376(23):2211-2222.